In-stent Repair and Vessel Reaction of STEMI Patients With OCT

Exclusion Criteria

• •CE1. Subjects with Cardiogenic shock. CE2. Subjects with severe heart failure (NYHA classification ≥ 3) or LVEF\<35%. CE3. Subjects with elevated serum creatinine level \>2.0mg/dL or undergoing dialysis therapy.
• •CE4. Subjects associated with drugs allergy (such as sirolimus, everolimus, stent alloys, contrast medium, heparin, clopidogrel or aspirin).
• •CE5. Subjects with bleeding tendency, active peptic ulcer, active gastrointestinal (GI) bleeding or other bleeding diathesis or coagulopathy, or refused a blood transfusion.
• •CE6. Subjects with cardiac stroke or with sequelae of stroke. CE7. Subjects with cebral tumor, Cerebral aneurysms, cerebral arteriovenous malformation (AVM), transient ischemic attack (TIA), permanent nerve defects, GI bleeding within 2 months, major operation within 6 weeks, or with abnormal counts of platelet and hemoglobin (Hb): platelet counts less than 1×106/mm3, Hb less than 10g/dL.
• •CE8. Subjects plan to undergo any operations within 6 months that may lead to anti-platelet therapy discontinuation.
• •CE9. Subjects are suffering from other serious illness, which may cause drop in life expectancy to less than 12 months.
• •CE10. Subjects were participating in another study of drug or medical device, which did not meet its primary endpoint.
• •CE11. Subject are considered unwilling to understand the trial requirements and refused to follow the treatment procedures.
• •CE12. Subject with Heart transplantation.
• •AE1. Target lesions with true bifurcation lesion (both main and branch vessel need implantation).
• •AE2. Target lesions with unprotected left main. AE3. Target lesions with more than 100mm in length. AE4. Target lesions with in-stent stenosis. AE5. Uncertain target lesions. AE6. Target lesion unsuitable for 6 months OCT follow up.